High Court To Weigh In On Amgen Class Cert. Quarrel

Law360, New York (June 11, 2012, 11:50 AM EDT) -- The U.S. Supreme Court on Monday agreed to hear an appeal of a Ninth Circuit decision that kept intact a shareholder class alleging Amgen Inc. misled investors about the safety of two top-selling anemia drugs, accusations Amgen says are based on statements that weren't material.

In a brief order, the high court granted Amgen's petition of a writ of certiorari to hear the appeal of the Ninth Circuit's November 8 decision. Justice Stephen Breyer recused himself from the certiorari decision, the order said.

The Ninth Circuit...
To view the full article, register now.